Jayasree Iyer – CEO, Access to Medicine Foundation
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Address: Postbus 184
2130 AD Hoofddorp
Tel: +31 23 56 80 300
Ferring is a speciality, research-driven biopharmaceutical company that identifies, develops, manufactures and markets innovative products in the fields of urology, reproductive health, gastroenterology and endocrinology.
From its origins as a distinctly Scandinavian company, Ferring has developed into a global business with operating units in most important pharmaceutical markets around the world.
Ferring’s vision is to be the partner of choice for patients, physicians and business associates offering a leading portfolio of products and services in its key therapeutic areas, using innovative methodologies to provide tailored treatments that function on the body’s own terms.
In two rented rooms in Malmö, Sweden, Dr. Frederik Paulsen founded Nordiska Hormon Laboratoriet in 1950, which in 1954 changed its name to Ferring. He named the company after the strong, closely knit community of people originating from the island Föhr who called themselves Feringers, and spoke Fering.
World leader in peptide hormones, Ferring became a pioneer in developing and selling pharmaceutical products based upon natural, pituitary-produced peptide hormones. Dr. Paulsen was convinced that these new compounds could be used to supplement deficiencies and correct abnormalities, thus playing an invaluable role in the treatment of life-threatening conditions.
Five decades later, Dr. Paulsen’s predictions have proved remarkably accurate. Today, peptides from Ferring are widely used in Ferring’s treatments. The development of the product MINIRIN (desmopressin), used to treat nocturnal enuresis, or bedwetting, formed the basis of Ferring’s international expansion and boosted revenues from the late 1980s on.
Gynaecology (Fertility and obstetrics), urology, gastroenterology, Child endocrinology and Child hematology.
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
See our Cookie Privacy Policy Here
